Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/‐Ribavirin in Patients Receiving Concomitant Acid‐Reducing Agents in Phase 3 Trials: 2019. (October 2015) - Shiffman, Mitchell